Amryt Pharma (Nasdaq:AMYT) - 주가, 뉴스 및 분석

AMYT 주식 개요

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases.

회사 소개

AMYT 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	5/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

보상

수익은 매년 53.88% 증가할 것으로 예상됩니다.

지난 5년 동안 수입이 매년 34.4% 증가했습니다.

위험 분석

위험 검사에서 AMYT 에 대한 위험이 감지되지 않았습니다.

Amryt Pharma plc 경쟁사

Evolus

NasdaqGM:EOLS

US$1.1b

ANI Pharmaceuticals

NasdaqGM:ANIP

US$1.1b

Collegium Pharmaceutical

NasdaqGS:COLL

US$1.1b

Liquidia

NasdaqCM:LQDA

US$926.5m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Amryt Pharma
과거 주가
현재 주가	US$14.70
52주 최고치	US$14.77
52주 최저치	US$6.41
베타	0.75
11개월 변경	0.96%
3개월 변경 사항	-0.14%
1년 변경 사항	86.55%
33년 변화	n/a
5년 변화	n/a
IPO 이후 변화	84.91%

최근 뉴스 및 업데이트

Recent updates

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

Oct 18

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

Sep 16

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Sep 08

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

Jul 14

Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept

Feb 04

Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder

Dec 23

Amryt Group's Lojuxta receives marketing approval in Brazil

Dec 09

주주 수익률

	AMYT	US Pharmaceuticals	US 마켓
7D	0.7%	-5.0%	-1.9%
1Y	86.5%	14.1%	30.4%

수익률 대 산업: AMYT 지난 1년 동안 14.1 %를 반환한 US Pharmaceuticals 산업을 초과했습니다.

수익률 대 시장: AMYT 지난 1년 동안 30.4 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is AMYT's price volatile compared to industry and market?
AMYT volatility
AMYT Average Weekly Movement	0.4%
Pharmaceuticals Industry Average Movement	9.4%
Market Average Movement	6.0%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

안정적인 주가: AMYT 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: AMYT 의 주간 변동성은 지난 1년 동안 16% 에서 0% 로 감소했습니다.

회사 소개

설립	직원	CEO	웹사이트
2015	289	Joe Wiley	www.amrytpharma.com

Amryt Pharma plc 기본 사항 요약

Amryt Pharma 의 수익과 매출은 시가총액과 어떻게 비교하나요?
AMYT 기본 통계
시가총액	US$940.67m
수익(TTM)	-US$790.00k
수익(TTM)	US$243.62m

3.9x

P/S 비율

-1,191x

P/E 비율

AMYT 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
AMYT 손익 계산서(TTM)
수익	US$243.62m
수익 비용	US$111.31m
총 이익	US$132.32m
기타 비용	US$133.11m
수익	-US$790.00k

최근 보고된 수익

Sep 30, 2022

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.012
총 마진	54.31%
순이익 마진	-0.32%
부채/자본 비율	64.3%

AMYT 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

AMYT 주식 개요

보상

위험 분석

Amryt Pharma plc 경쟁사

NasdaqGM:EOLS

US$1.1b

NasdaqGM:ANIP

US$1.1b

NasdaqGS:COLL

US$1.1b

NasdaqCM:LQDA

US$926.5m

가격 내역 및 성능

최근 뉴스 및 업데이트

Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH

Amryt Announces European Commission Approves Mycapssa® for the Treatment of Acromegaly

Amryt Pharma plc Re-Affirms Revenue Guidance for the Year 2022

Amryt Pharma plc to Report Q3, 2022 Results on Nov 03, 2022

Amryt Announces COMP Adopts Positive Opinion on Orphan Disease Designation for Mycapssa for Treatment of Acromegaly

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta (Metreleptin)

Recent updates

Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH

Amryt Announces European Commission Approves Mycapssa® for the Treatment of Acromegaly

Amryt Pharma plc Re-Affirms Revenue Guidance for the Year 2022

Amryt Pharma plc to Report Q3, 2022 Results on Nov 03, 2022

Amryt Announces COMP Adopts Positive Opinion on Orphan Disease Designation for Mycapssa for Treatment of Acromegaly

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta (Metreleptin)

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez(R) in Great Britain

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez(R) in Great Britain

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Amryt Pharma plc Provides Earnings Guidance for the Full Year 2022

Amryt Pharma plc to Report Q2, 2022 Results on Aug 04, 2022

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa(R) (oral octreotide) for the Treatment of Carcinoid Syndrome

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA

Amryt Announces European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB

Amryt's Filsuvez gets approval in EU to treat rare skin disorder

Amryt Presents Data for Mycapssa (Oral Octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa(R) (oral octreotide) at ENDO 2022

Amryt Pharma plc, Annual General Meeting, Jun 30, 2022

Amryt Pharma plc Announces New Patent for Mycapssa®

Amryt Pharma plc Reaffirms Revenue Guidance for Fiscal Year 2022

CHMP Adopts positive opinion for Filsuvez(R) for the treatment of Dystrophic and Junctional EB

Amryt Pharma plc to Report Q1, 2022 Results on May 04, 2022

Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients

Amryt Announces Successful Bioavailability Study for Mycapssa® (Octreotide Capsules)

Amryt Receives Complete Response Letter from the U.S. Food and Drug Administration for Oleogel-S10 NDA

Amryt Announces Oleogel-S10 EMA Regulatory Update

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide)

The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients

Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions

Amryt Pharma plc Provides Update on Regulatory Review Process for Oleogel-S1

Amryt Announces the Cancellation of Admission of Its Ordinary Shares to Trading on AIM

Amryt Pharma plc Revises Revenue Guidance for the Year 2021

Amryt Pharma plc Announces Earnings Guidance for the Fiscal Year 2021

Amryt Pharma plc completed the acquisition of Chiasma, Inc. from MPM Capital and others.

U.S. Food and Drug Administration Confirms Amryt’s New Drug Application for Oleogel-S10 Will Not Require an Advisory Committee Meeting

U.S. Food and Drug Administration Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa

Amryt Pharma plc entered into an agreement to acquire Chiasma, Inc. from MPM Capital and others for approximately $290 million.

Chiasma surges on merger agreement with Amryt

Amryt and Medison Pharma Canada Sign Distribution Agreement for Myalepta (Metreleptin) in Canada

Amryt Pharma plc to Report Q4, 2020 Results on Mar 04, 2021

Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel

Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept

Amryt Pharma plc Receives Reimbursement Approval from Nice for Myalepta in England and Wales

Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder

Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (Lomitapide) in Saudi Arabia

Amryt Group Receives Marketing Authorisation Approval for Lojuxta in Brazil

Amryt Group's Lojuxta receives marketing approval in Brazil

Amryt Pharma plc Raises Sales Guidance for the Full Year 2020

Amryt Announces Positive Results from Phase 3 Trial of Filsuvez® in Epidermolysis Bullosa

Amryt Signs Distribution Agreement with Swixx BioPharma AG

Amryt and Swixx Sign Distribution Deal for Lojuxta

Amryt Pharma plc to Report Q3, 2020 Results on Nov 05, 2020

Amryt Pharma Intends to Cancel the Admission of the Ordinary Shares to Trading on the Euronext Growth Market

주주 수익률

가격 변동성